Abstract
Anti-angiogenic treatments have recently been incorporated as a milestone in the management of metastatic renal cell carcinoma. This retrospective study explores this new practice in 94 patients treated by sorafenib, bevacizumab or sunitinib in the department of oncology of CHU of Bordeaux in a 32 months period. The adverse effects reported are similar than those from prospective trials but for some different in frequency or severity. Efficacy of these drugs appeared more modest than expected from phase III trials. An objective response rate or stabilisation longer than six month was seen in 35% of the patients. Median overall survival was 14.1 months (IC 95%: 8.3-18.7 months). Nevertheless, the population considered in this study had a worse prognosis with more patients with an altered general status (OMS 2 or 3: 13.8%).
MeSH terms
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Benzenesulfonates / adverse effects
-
Benzenesulfonates / therapeutic use*
-
Bevacizumab
-
Brain Neoplasms / secondary
-
Carcinoma, Renal Cell / blood supply
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary
-
Drug Administration Schedule
-
Female
-
Humans
-
Indoles / adverse effects
-
Indoles / therapeutic use*
-
Kidney Neoplasms / blood supply
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Pyrroles / adverse effects
-
Pyrroles / therapeutic use*
-
Retrospective Studies
-
Sorafenib
-
Sunitinib
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Benzenesulfonates
-
Indoles
-
Phenylurea Compounds
-
Pyridines
-
Pyrroles
-
Niacinamide
-
Bevacizumab
-
Sorafenib
-
Sunitinib